TA-02

• Description :

  TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) [1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; p38 MAPK

• Type :

  Reference compound

• Related Pathways :

  Autophagy; MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/TA-02.html

• Purity :

  99.85

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=CC=C4F)=N2

• Molecular Formula :

  C20H13F2N3

• Molecular Weight :

  333.33

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J Mol Cell Cardiol. 2015 Mar;80:56-70.|[2]Jiedong Liang, et al. The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling. Exp Ther Med. 2019 Mar;17 (3) :1688-1696.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1784751-19-4]